March 2016

Kaufman recently coined the term "precision immunology" to describe the use of host, immune system and tumor factors as biomarkers to select immunotherapy approaches. But, are we ready to integrate precision immunology into clinical practice?

The combination of pazopanib (Votrient) and cetuximab (Erbitux) showed a disease control rate of 77% in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy produced long-term control for patients with HPV-, locoregionally advanced head and neck squamous cell carcinoma with a poor prognosis.

Despite what many believe, not all radiopharmaceuticals are just for pain palliation, according to Phillip J. Koo, MD.

Despite the letdown of prior research, the future looks bright for immunotherapies and novel targeted approaches for patients with gliomas, many of which have already been developed for other types of cancer.

Promising early phase clinical trials have led to the initiation of the phase III JUNIPER trial, which is assessing abemaciclib (LY2835219) for patients with previously treated KRAS-mutant lung cancer, a traditionally hard to treat genetic subtype.